Our ‘quick’ screen program allows companies to obtain a preliminary dataset in a cost-effective manner. We leverage a combination of our cell and assay platforms in designing assays that can help address important questions in drug screening. These assays are offered on a weekly basis for a fixed fee/fixed readout.
To maintain continuity, we can study our cells and assay platforms in a synergistic manner across multiple assay platforms. The data generated across various platform using a common cell line allows cross comparison of the various factors that maybe involved in a drug’s mechanism of action or function.
We seek partnerships with companies with similar interests of changing the paradigm of drug development. We welcome conversations that help us think outside the box and where we can leverage our expertise, tools, capabilities and platforms for advancing research and development.